



## **Viral Diseases and the Existing Comorbidities: An Overview of Disease Development, Progression, and Therapeutics**

Guest Editors:

**Dr. Irfan A. Rather**

**Dr. Suriya Rehman**

**Dr. Yan Yan HOR**

**Dr. Lew Lee Ching**

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### **Message from the Guest Editors**

The current global outbreak of SARS-CoV-2 has indicated that the population with pre-existing comorbidities like age, chronic inflammation, hypertension, cardiovascular disease, diabetes, etc., are vulnerable to a much-increased risk of morbidity and mortality viral diseases.

This Special issue will focus on discussing the immune response to viral infections and the disease development among patients with pre-existing comorbidities. Moreover, there is a need to explore how the underlying disease etiologies aggravate the disease progression. Hence, it is of paramount importance to analyze the challenges and options associated with the new and repurposed therapies and the scope of prebiotics or probiotics and vaccine development to prevent viral infections in patients with pre-existing comorbidities. As the current pandemic continues to escalate, we hope this special issue offers healthcare providers and researchers a greater and extensive understanding of the effect of pre-existing comorbidities on developing and treating viral infections.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)